Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Xilio Therapeutics Inc (NASDAQ: XLO) was $0.67 for the day, down -2.69%% from the previous closing price of $0.69. In other words, the price has decreased by -$2.69% from its previous closing price. On the day, 0.75 million shares were traded. XLO stock price reached its highest trading level at $0.69 during the session, while it also had its lowest trading level at $0.661.
Ratios:
Our analysis of XLO’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 1.65. For the most recent quarter (mrq), Quick Ratio is recorded 1.96 and its Current Ratio is at 1.96. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Chardan Capital Markets on December 21, 2022, initiated with a Buy rating and assigned the stock a target price of $7.
On January 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $36.
On November 16, 2021, Raymond James started tracking the stock assigning a Outperform rating and target price of $31.Raymond James initiated its Outperform rating on November 16, 2021, with a $31 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 16 ’25 when Shannon James Samuel bought 45,000 shares for $0.69 per share. The transaction valued at 30,870 led to the insider holds 45,000 shares of the business.
Shannon James Samuel bought 25,000 shares of XLO for $17,215 on Jun 17 ’25. The Director now owns 70,000 shares after completing the transaction at $0.69 per share. On Jun 16 ’25, another insider, Russo Rene, who serves as the PRESIDENT AND CEO of the company, bought 36,289 shares for $0.68 each. As a result, the insider paid 24,680 and bolstered with 281,172 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XLO now has a Market Capitalization of 35729760 and an Enterprise Value of -46514876. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.74 while its Price-to-Book (P/B) ratio in mrq is 3.24. Its current Enterprise Value per Revenue stands at -5.016 whereas that against EBITDA is 0.842.
Stock Price History:
The Beta on a monthly basis for XLO is 0.01, which has changed by -0.25555557 over the last 52 weeks, in comparison to a change of 0.10163462 over the same period for the S&P500. Over the past 52 weeks, XLO has reached a high of $1.70, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is -13.21%, while the 200-Day Moving Average is calculated to be -23.48%.
Shares Statistics:
XLO traded an average of 1.25M shares per day over the past three months and 544140 shares per day over the past ten days. A total of 51.78M shares are outstanding, with a floating share count of 16.30M. Insiders hold about 68.53% of the company’s shares, while institutions hold 16.12% stake in the company. Shares short for XLO as of 1748563200 were 791482 with a Short Ratio of 0.63, compared to 1745971200 on 351157. Therefore, it implies a Short% of Shares Outstanding of 791482 and a Short% of Float of 2.2399999999999998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
